How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

238 results for

Emergency Pediatric Dosing 12-14 kilogram


Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

221. Study to Find Out if Intensive Diabetes Clinic and Continuous Glucose Monitors Help Teenagers With Diabetes

, and emergency phone calls for hyperglycemia and ketonuria will be tracked. Secondary Outcome Measures : Insulin dose changes [ Time Frame: Baseline and every month for four months ] Insulin doses in units per kilogram per day will be calculated at each visit. Episodes of Hypoglycemia (blood glucose <70 mg/dL) [ Time Frame: Every month for four months ] Blood glucose meter downloads will be used to tabulate the number of episodes of blood glucoses < 70 mg/dL. At each visit patients will be asked to recall (...) Inclusion Criteria: Type 1 diabetes mellitus of at least 12 months duration, followed by Rainbow Babies and Children's Pediatric Endocrinology and Diabetes Division Most recent HbA1c >= 8.5% Patients must be willing to check their blood sugar at least 4 times daily while wearing the CGM Patients and families must be willing to come to diabetes clinic once a month for 4 months Exclusion Criteria: Inability to understand and/or speak the English language Pregnancy Psychological counseling with Dr. Rebecca

2010 Clinical Trials

222. Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients

. Samples were collected at the following times: pre-dose; 30 minutes, 1, 2, 4, 7, and 12 hours post-dose on Day 14 of the respective treatment period. Due to non-quantifiable values, it was not possible to derive AUC(0-12). Cmax on Day 14 of the Respective Treatment Period [ Time Frame: Day 14 of the respective treatment period ] Cmax is defined as the maximum observed concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 30 minutes, 1, 2 (...) , 4, 7, and 12 hours post-dose on Day 14 of the respective treatment period. Tmax and t at Day 14 of the Respective Treatment Period [ Time Frame: Day 14 of the respective treatment period ] tmax is defined as the time to reach the observed maximum concentration, and t is defined as the time of the last observed quantifiable concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 30 minutes, 1, 2, 4, 7, and 12 hours post-dose on Day 14

2010 Clinical Trials

223. Magnesium in Crisis

and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. Identifier: NCT01197417 Recruitment Status : Completed First Posted : September 9, 2010 Results First Posted : September 7, 2015 Last Update Posted : January 27, 2016 Sponsor: Medical College of Wisconsin Collaborator: Pediatric Emergency Care Applied Research Network Information (...) Outcome Measures Go to Primary Outcome Measures : Hospital Length of Stay (Hours) [ Time Frame: From the time of the start of first study med infusion until hospital discharge or 12 hours after the last IV opioid, whichever occurs first, up to 10 days post enrollment ] Secondary Outcome Measures : Number of Morphine Equivalents Per Kilogram of Body Weight Used During Hospitalization [ Time Frame: Total morphine equivalents used during the hospitalization will be recorded on the day of discharge, up

2010 Clinical Trials

224. PR-018: An Open-Label, Safety Extension of Study PR-011

or apple sauce will be administered orally starting at the same dose as administered at the end of study PR-011 (NCT01100606), with dose increments of 3,000 lipase units. The dose will be adjusted based on participants' age and body weight. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day unless clinically indicated. Total duration of study treatment will be up to 12 months. Other Name: Zenpep® (pancrelipase) 3,000 lipase units delayed release capsules Outcome (...) of Aptalis (formerly Eurand) study PR-011 (NCT01100606) in pediatric participants with EPI due to CF. The study will be carried out in participants who completed the PR-011 study. The study is comprised of 5 visits: an enrollment visit, treatment visit 1 (3 months), treatment visit 2 (6 months), treatment visit 3 (9 months) and treatment visit 4 (12 months). Once determined eligible for participation, participants will be enrolled into the study. Study Design Go to Layout table for study information

2010 Clinical Trials

225. Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients

Index (BMI; in Kilograms Per Square Meter [kg/m^2]) [ Time Frame: Baseline, Month 12 ] BMI = Weight (kg)/(Height*Height) (square meters [m^2]). Percentage of Participants With New-Onset Diabetes [ Time Frame: From Baseline to On-Therapy Month 12, from Baseline to On-Therapy Month 24, and from On-Therapy Month 12 up to On-Therapy Month 24 ] Participants were considered as having new onset diabetes during the On-therapy period if any of the below events emerged from baseline to Month 24: 1) at least (...) and 24 ] GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS. Calculated GFR Using MDRD (On-Therapy Analysis) [ Time Frame: Baseline, Months 6, 12, 18, and 24 ] GFR was calculated using the MDRD equation using either serum creatinine traceable to IDMS or serum creatinine not traceable to IDMS. Baseline was defined as the last nonmissing assessment before or on the date of the first dose of test article. Change From

2009 Clinical Trials

226. Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients

reported. Incremental Recovery [ Time Frame: Days 1, 15, 50, Months 6, 18 and Final visit (up to Month 24) ] Incremental recovery was the increase in circulating FVIII activity for every international unit (IU) of ReFacto AF administered per kilogram of body weight. It was measured in international units per deciliter (IU/dL) per international units per kilogram (IU/kg). Terminal Elimination Half Life of ReFacto AF (t1/2) [ Time Frame: Pre-dose, 0.5, 1, 3, 6, 9, 24, 28, 32, 48 hours post-dose on Day 1 (...) for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events. Eligibility Criteria Go to Information from the National Library

2009 Clinical Trials

227. Iodine

UNSAFE when taken by mouth in high doses. Do not take more than 1100 mcg of iodine per day if you are over 18 years old; do not take more than 900 mcg of iodine per day if you are 14 to 18 years old. Higher intake has been shown to cause thyroid problems in the newborn in some cases. Autoimmune thyroid disease : People with autoimmune thyroid disease may be especially sensitive to the harmful side effects of iodine. A type of rash called dermatitis herpetiformis : Taking iodine can cause worsening (...) vegetables Gloitrogens, which are chemicals that are present in raw cruciferous vegetables, might interfere with how the thyroid absorbs iodine. What dose is used? The following doses have been studied in scientific research: ADULTS BY MOUTH : For iodine deficiency : Consumption of iodized salt is recommended in most cases. For most people, iodized salt containing 20-40 mg of iodine per kilogram of salt is recommended. If salt consumption is less than 10 grams per person per day, the amount of iodine

2009 National Centre for Complementary and Alternative Medicine

228. Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections

(for ages 12 to 17 years): 5 milligrams/kilogram (mg/kg) Age Group 2 (for ages 7 to 11 years): 7 mg/kg Age Group 3 (for ages 2 to 6 years): 9 mg/kg Age Group 4 (for ages 1 to <2 years): 10 mg/kg Drug: Daptomycin Other Name: Cubicin Active Comparator: Standard of Care (SOC) The comparator agent for this study was the SOC treatment and dosage deemed appropriate by the Investigator. The recommended SOC agents were IV vancomycin, IV clindamycin, and IV semisynthetic penicillins every 24 hours for up to 14 (...) days. Drug: Standard of Care (SOC) Other Name: nafcillin, oxacillin, cloxacillin Outcome Measures Go to Primary Outcome Measures : Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: Baseline through 14 days after last dose of study drug ] A TEAE was defined as any treatment-emergent adverse event (AE) that occurred from the time of first dose of the study drug through the last study evaluation or pre-existing adverse AEs that were aggravated in severity

2008 Clinical Trials

229. CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Date : December 2014 Resource links provided by the National Library of Medicine related topics: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: 5 microgram per kilogram (mcg/kg) Participants received intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle. Drug: CAT-8015 (Moxetumomab Pasudotox) Participants received intravenous (...) infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle. Experimental: 10 microgram per kilogram (mcg/kg) Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle. Drug: CAT-8015 (Moxetumomab Pasudotox) Participants received

2008 Clinical Trials

230. Propionic Acidaemia

and allows genetic counselling. If the diagnosis is not made in life it is unlikely to be made post-mortem. However, it is likely that the full work-up of patients presenting with typical (but nonspecific) signs and symptoms will include a wider range of tests in keeping with the differential diagnoses outlined. Inborn errors of metabolism present in a variety of ways (five main presentations have been observed) and faced with an infant's deteriorating condition, emergency treatment and investigations (...) amino acids should be permitted in very limited amounts. A protein intake below 1.5 grams per kilogram body weight per day is often required. If breast-feeding occurs it must be monitored carefully. [ ] Diet should be individualised with the aim of restricting propiogenic substrates (valine, methionine, isoleucine, threonine and odd chain fatty acids), while encouraging normal protein synthesis and preventing protein catabolism, amino acid deficiencies and growth restriction. L-carnitine

2008 Mentor

231. Canadian clinical practice guidelines on the management and prevention of obesity in adults and children

adipose tissue over 7 years in women. Int J Obes Relat Metab Disord 1996;20:618-24. 13. Enzi G, Gasparo M, Biondetti PR, et al. Subcutaneous and visceral fat distribution according to sex, age, and overweight, evaluated by computed tomography. Am J Clin Nutr 1986;44:739-46. 14. Kotani K, Tokunaga K, Fujioka S, et al. Sexual dimorphism of age-related changes in whole-body fat distribution in the obese. Int J Obes Relat Metab Disord 1994;18: 207-12. 15. Guthrie JR, Dennerstein L, Taffe JR, et al (...) to provide ongoing counselling about dietary and lifestyle management, education and, perhaps most impor- tant, ongoing support to the patient so that she maintains the dietary and lifestyle changes over the long-term. Dietary and lifestyle interventions Rationale: Dietary and lifestyle interventions aimed at decreas- ing energy intake and increasing energy expenditure through a balanced dietary and exercise program are an essential compo- nent of all weight management programs. In chapter 12, we provide

2007 CPG Infobase

232. Care and Maintenance to Reduce Vascular Access Complications

the routine use of the veins of the lower extremities due to the increased risk of embolism, thrombophlebitis of and infection (CDC, 2002; INS, 2000; Tagalakis, 2002); ¦ Choose the smallest gauge catheter to accommodate the prescribed therapy (INS, 2000); ¦ Choose a vein with a diameter and blood flow rate for adequate hemodilution of prescribed therapy. For example: a one time dose of dilantin which has a pH of 12, should be infused using a 22 gauge PVAD into a vein with a high blood flow rate (...) ICU/Telemetry, Leamington District Memorial Hospital, Leamington, Ontario Gina Bagger, RN, BScN Former Vascular Access Resource Nurse, The Hospital for Sick Children, Toronto, Ontario Nancy A. Bauer, Hon.BA, Professional Practice Leader, Leamington District Memorial Hospital, Hon.Bus. Admin., RN, ET Leamington, Ontario Michele Bellows, RN, CINA(C) Director of Care and Emergency Room, Stoneridge Manor/Carleton Place and District Memorial, Carleton Place, Ontario Joan Bennett, RN, CINA(C) RN

2005 Registered Nurses' Association of Ontario

233. Nursing Management of Hypertension

the scope of nursing practice. The Heart and Stroke Foundation is currently leading the High Blood Pressure Strategy, which is a five-year plan with the potential to show a significant positive impact on hypertension in Ontario. This plan is comprised of two major components, namely enhancement of primary healthcare providers’ management of hypertensive patients, and research into two emerging areas. These research endeavours include studying the role of systolic blood pressure in patients aged 45 (...) and older, as well as examining issues about the social determinants of high blood pressure. Several other key activities will inform these two main components, such as a prevalence survey to update the 1992 Heart Health Survey statistics for hypertension in Ontario, a strong evaluation plan focused on both the 5-year impact of the strategy and its major elements, as well as advocacy efforts to speak to prospective system-based matters that emerge during the course of the plan. Fundamentally, to enhance

2005 Registered Nurses' Association of Ontario

234. Paediatric Endocrine Tumour Guidelines

Consensus Development Group 4 Development and Purpose of Consensus Recommendations 8 and a National Registry Process of Development and Use of the Consensus Recommendations 9 Types of Evidence for Consensus Recommendations 10 Introduction Summary for Consensus Recommendations 11 Details for Patient Registration 12 Abbreviations 14 1.1 CHAPTER 1 16 Craniopharyngioma 2.1 CHAPTER 2 47 Adreno-Cortical Tumours 3.1 CHAPTER 3 64 Differentiated Thyroid Carcinoma 4.1 CHAPTER 4 81 Phaeochromocytoma 5.1 CHAPTER 5 (...) Adenomatous Polyposis FDG 18 Fluoro-deoxy-glucose FSH Follicle Stimulating Hormone FHH Familial Hypercalcaemic Hypocalciuria FNA Fine Needle Aspirate FT 3 Triiodothyronine FT 4 Thyroxine, Levothyroxine GBq Giga Becquerels GnRH Gonadotropin Releasing Hormone Gsa Stimulatory a subunit of the G-protein IGF-1 Insulin-like Growth Factor-1 IGF-BP3 Insulin-like Growth Factor-Binding Protein-3 IM Intramuscular IV Intravenous Kg Kilogram Abbreviations 14 48382 Insert Final 1/11/05 5:07 pm Page 14Paediatric

2005 British Association of Endocrine and Thyroid Surgeons

235. Effectiveness of Arginine as a Treatment for Sickle Cell Anemia

assigned to receive twice daily doses of either a low dose of arginine, a high dose of arginine, or placebo for 12 weeks. Study visits will occur at baseline, three times during Month 1, and Weeks 8, 12, 14, and 16. Each study visit will include an echocardiogram to measure heart activity, blood collection, and a medical history review to identify adverse events, pain medication usage, headaches, emergency department visits, and hospitalizations. Study Design Go to Layout table for study information (...) Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger. Outcome Measures Go to Primary Outcome Measures : Gardos Channel Activity [ Time Frame: 12 weeks after randomization ] Gardos channel activity: a calcium (Ca2+)-activated

2007 Clinical Trials

236. Budesonide Inhalation Suspension for Acute Asthma in Children

doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 2 Years to 18 Years (Child, Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Chief complaint of "respiratory distress", "asthma", "trouble breathing", or "reactive airway disease" Males or females age 2 to 18 years Weight greater than or equal to 10 kilograms Two or more prior Emergency (...) : August 2012 Keywords provided by Children's Hospital of Philadelphia: Asthma Acute Treatment Children Pediatric Inhaled corticosteroid Budesonide Budesonide inhalation suspension Asthma score Emergency Emergency Department Asthma flare Clinical trial Randomized clinical trial Randomized trial Pulmonary index score Hospitalization Moderate asthma Severe asthma Mixing budesonide Budesonide admixture Albuterol Continuous albuterol Ipratropium bromide Additional relevant MeSH terms: Layout table for MeSH

2006 Clinical Trials

237. Safety and Pharmacokinetic (PK) Study of Intravenous (IV) Acetaminophen Administration in Pediatric Inpatients

(called pharmacokinetics) is an important step in learning what the best dose of acetaminophen for children should be. We are also interested in learning about the safety of this medication when given to children. Condition or disease Intervention/treatment Phase Pain Fever Drug: IV Acetaminophen Phase 1 Detailed Description: A Prospective, Multi-Center, Randomized, Open-Label, Single and Repeated Dose, 48 Hour Study, of Intravenous Acetaminophen in Pediatric Inpatients to Determine Pharmacokinetics (...) (PK) and Safety in Acute Pain and Fever Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 75 participants Allocation: Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Prospective, Multi-Center, Randomized, Open-Label, Single and Repeated Dose, 48 Hour Study, of Intravenous Acetaminophen in Pediatric Inpatients to Determine Pharmacokinetics (PK

2007 Clinical Trials

238. Prescribing Errors in a Pediatric Emergency Department. (PubMed)

Prescribing Errors in a Pediatric Emergency Department. To determine the frequency, prescriber, and type of prescribing errors in written in-house orders and ambulatory prescriptions in a pediatric emergency department (PED).A 17-day retrospective chart review and a 6-month retrospective ambulatory prescription review in a PED for medications with weight-based dosing. Orders and prescriptions were checked for prescriber identification number, route, weight-based target dose in milligrams per (...) kilogram, frequency, correct dosing, and drug allergies. Narcotics were excluded from the prescription analysis.Forty-seven (12.5%) of 377 in-house orders and 37 (19.4%) of 191 individual charts contained at least 1 error: 4 (1.1%) orders contained an incorrect dose, 41 (10.8%) were written incorrectly, and 2 (0.5%) contained an incorrect dose and were written incorrectly. Thirty (4.3%) of 696 ambulatory prescriptions contained 1 error: 14 (2.0%) contained an incorrect dose, and 16 (2.3%) were written

2007 Pediatric Emergency Care

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>